Samarium (153Sm) lexidronam is a chelated complex of samarium isotope and EDTMP that concentrates in areas with high bone turnover such as sites of metastases to relieve pain associated with osteoblastic metastatic bone lesions. Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone.
- Mechanism
- Curator reviewed
Samarium Sm 153 lexidronam targets the sites of new bone formation, concentrating in regions of the bone that have been invaded with metastatic tumor. The drug goes to the source of cancer bone pain and irradiates the osteoblastic tumor sites resulting in relief of pain. The onset of pain relief was experienced as early as one week in the majority of patients.
- Primary indication
- Investigated for use/treatment in bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.Curator reviewed · 1 structured indication
- Formula / weight
- C6H17N2O12P4Sm · 586.021 g/mol (avg)
- First approval
- United States, 1997 · European Union, 2016
- Also known as
- 153SM-EDTMP · Samarium (153 Sm) lexidronam · Samarium Sm-153 lexidronam · Samarium-153 lexidronam · Samarium-153-EDTMP
- Brand names
Resolves to
JSTADIGKFYFAIY-GJNDDOAHSA-KSMILES[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=OWhat you can answer from here — as of August 30, 2026
Which other approved drugs treat the same conditions as Samarium (153Sm) lexidronam, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account